Drug analysis system

Abstract

The goal is to provide comprehensive drug information by obtaining information on all drugs registered in the drug master database. [Solution] The system includes a drug storage unit 10 that acquires drug information registered in drug masters of multiple medical institutions and stores it as adopted drug information, a drug analysis unit 11 that analyzes the adopted drug information and obtains analysis information for users, including at least one of a pharmaceutical company and a medical institution, and an information provision unit 12 that provides the analysis information to the user.

Description

Technical Field

[0001] The present invention relates to a drug analysis system that acquires and analyzes information on drugs registered in the drug master of a plurality of medical institutions, and provides the analysis information to pharmaceutical manufacturers and medical institutions.

Background Art

[0002] Conventionally, for the purpose of enabling the collection and provision of more objective statistical information on drugs, Japanese Patent Application Laid-Open No. 2018-81529 discloses acquiring, via a network, information on at least adopted drugs among the electronic medical record information input in a plurality of medical institution terminals, constructing an adopted drug database from the acquired information on adopted drugs, and referring to the adopted drug database for a business operator terminal to provide statistical information on adopted drugs by region.

Prior Art Documents

Patent Documents

[0003]

Patent Document 1

Summary of the Invention

Problems to be Solved by the Invention

[0004] However, in the system disclosed in Patent Document 1, in order to acquire information on adopted drugs, prescription drugs adopted as prescription orders among the electronic medical record information are extracted as "adopted drugs" (see paragraph number 0025 of Patent Document 1). In this method, only the drugs actually prescribed can be extracted, and it is not possible to comprehensively analyze the drugs registered in the drug master.

[0005] The present invention has been made in view of the above points, and an object thereof is to provide drug information that can be used for various analyzes including information other than prescription drugs adopted as prescription orders by obtaining information on drugs registered in the drug master. [Means for solving the problem]

[0006] The drug analysis system of the present invention is A drug storage unit that retrieves drug information registered in the drug masters of multiple medical institutions and stores it as adopted drug information, A drug analysis department analyzes the aforementioned drug adoption information to obtain analytical information for users, including at least one of the pharmaceutical companies and medical institutions. An information provision unit that provides the aforementioned analysis information to the user, It is characterized by having the following features.

[0007] The drug analysis system of the present invention includes a drug storage unit that acquires drug information registered in drug masters of multiple medical institutions and stores it as adopted drug information. Therefore, it is possible to comprehensively analyze drugs registered in drug masters. A medical institution refers to an organization that performs medical procedures, such as a hospital, clinic, medical office, or pharmacy.

[0008] A preferred example of the drug analysis system of the present invention is: The aforementioned analysis information includes target drug information relating to the drug in question. The aforementioned drug information, The master adoption rate represents the percentage of the target drug that is registered in the drug master and is available for prescription, and The adoption / deletion rate represents the percentage of drugs that, after being registered in the drug master and deemed prescribable, are subsequently removed from the list of drugs that can be prescribed and are therefore deemed unprescriptionable. It is equipped with.

[0009] In a preferred example of the drug analysis system of the present invention, the master adoption rate allows us to understand whether a specific drug of interest is registered in the drug master. Furthermore, the adoption / deletion rate allows us to understand whether a specific drug of interest has been deleted from the drug master or is not available for prescription. Here, "prescription" means that the drug is used by injection, oral administration, topical application, etc., or that a prescription is issued for the drug to be used.

[0010] A preferred example of the drug analysis system of the present invention is: The aforementioned analysis information includes target drug information relating to the drug in question. The aforementioned drug information, The adoption speed is the period from the start of sales of the drug to its registration in the drug master database. The prescription speed of the drug in question is the period from the start of sales of the drug until it becomes available for prescription. The period during which the drug in question was registered in the drug master and available for prescription is the registration usage period. The in-hospital prescription adoption rate represents the percentage of the target drug that is registered in the drug master and designated as an in-hospital prescription drug that can be dispensed within the hospital. The outpatient prescription adoption rate represents the percentage of the target drug that is registered in the drug master and designated as an outpatient prescription drug that can be prescribed outside the hospital. The frequently used drug adoption rate represents the percentage of the target drug that is registered in the drug master and designated as a frequently used drug. The provisional adoption rate represents the percentage of the target drug that is registered in the drug master and designated as provisionally adopted. It must have one or more of the following.

[0011] According to a preferred example of the drug analysis system of the present invention, more detailed information about the drug can be obtained.

[0012] A preferred example of the drug analysis system of the present invention is: The aforementioned analysis information includes comparative drug information that compares multiple drugs, The aforementioned comparative drug information, Drug adoption comparison information, which represents the adoption rate of individual drugs registered and available for prescription in drug masters at multiple medical institutions. Information on drugs that are candidates for deletion, specifically drugs that are registered in the drug master data of a particular medical institution and are available for prescription, but are not registered in or available for prescription in the drug master data of other medical institutions. Candidate drug information regarding drugs that are not registered in the drug master of a specific medical institution or are not available for prescription, but are registered in the drug master of other medical institutions and are available for prescription. Manufacturer difference information representing the occupancy rate for each pharmaceutical company among drugs that are registered in the drug masters of multiple medical institutions and are available for prescription. Group adoption consideration information regarding drugs that are registered in the drug masters of only some of the medical institutions within a group by comparing the drug masters of the medical institutions belonging to a specific group of medical institutions. It includes one or more of the above.

[0013] According to a preferred example of the drug analysis system of the present invention, a plurality of drugs in the drug masters of a plurality of medical institutions can be compared. Note that the group is intended to be a collection of those medical institutions when there are circumstances such as the management entities of a plurality of medical institutions being the same or a plurality of medical institutions being in partnership with each other.

[0014] A preferred example of the drug analysis system of the present invention is In-hospital adoption drug information regarding drugs that are registered as in-hospital prescription drugs in the drug master of a specific medical institution but are not registered as in-hospital prescription drugs in the drug masters of other medical institutions. Frequent use drug information regarding drugs that are registered as frequently used drugs in the drug master of a specific medical institution but are not registered as frequently used drugs in the drug masters of other medical institutions. It includes one or more of the above.

[0015] According to a preferred example of the drug analysis system of the present invention, more detailed drug information can be grasped.

Advantages of the Invention

[0016] As described above, according to the drug analysis system of the present invention, by obtaining information on drugs registered in the drug master, it is possible to provide drug information that can be used for various analyses including information other than prescription drugs adopted as prescription orders.

Brief Description of the Drawings

[0017] [Figure 1] This is a schematic diagram of a drug analysis system according to an embodiment of the present invention. [Figure 2] This is a diagram for explaining an example of a drug master. [Figure 3] This is a diagram for explaining an example of analysis information. [Figure 4] This is a diagram for explaining the master adoption rate, etc. [Figure 5] This is a diagram for explaining the adoption deletion rate. [Figure 6] This is a diagram for explaining the adoption speed, etc. [Figure 7] This is a diagram for explaining the comparison information of adopted drugs. [Figure 8] This is a diagram for explaining the information of drugs to be deleted candidates, etc. [Figure 9] This is a diagram for explaining the manufacturer difference information. [Figure 10] This is a diagram for explaining the information for considering adoption within a group. [Figure 11] This is a diagram for explaining the information of drugs adopted in the hospital. [Figure 12] This is a diagram for explaining the information of frequently used drugs. [Figure 13] This is another diagram for explaining the information of frequently used drugs. [Figure 14] This is a diagram for explaining the hospital master.

Mode for Carrying Out the Invention

[0018] Hereinafter, embodiments of the drug analysis system 1 of the present invention will be described in detail with reference to the accompanying drawings. The drug analysis system 1 of the present invention is implemented using a computer (not shown). For example, programs including the operating system necessary for the computer's operation and the information (data) to be stored are stored in a storage device consisting of secondary memory, etc. Furthermore, the analysis of the information is performed by a control device consisting of a CPU (central processing unit) and primary memory, etc., which reads the programs and data from the storage device, executes the programs, and performs arithmetic processing on the data. This control device not only performs arithmetic processing on the data but also controls the entire computer, including the storage device and input / output devices. In addition, input / output devices such as keyboards, mice, monitors, printers, and input / output terminals are used for data input and output. Furthermore, telecommunication lines such as the Internet are used for sending and receiving data between multiple computers and terminal devices such as tablet terminals.

[0019] Referring to Figure 1, the outline of the drug analysis system 1 of this embodiment will be described. The drug analysis system 1 of this embodiment is a system that obtains drug information from drug masters of multiple medical institutions, analyzes that information, and provides it to users. These drug masters of multiple medical institutions and the drug analysis system 1 are connected using a telecommunications line 2. In addition, the drug analysis system 1 of this embodiment and the user's terminal equipment are connected using a telecommunications line 3.

[0020] The drug master, as shown in Figure 2, is a table that determines which drugs can be prescribed at a given medical institution. Here, the drug master for the internal medicine department of Hospital A is used as an example. The drug master has the following items (columns): drug name, pharmaceutical company, drug master registration date, prescription start date, and adoption end date. The drug name is the name used to identify the drug. The pharmaceutical company is the name of the company that manufactures or sells the drug. The drug master registration date is the date the drug was registered in the drug master, or the date the record for that drug was created. The prescription start date is the date the drug can actually be prescribed. This is because sometimes drugs are registered in the drug master in advance, and then made available for prescription when preparations for prescribing the drug are complete at the medical facility. Of course, it is also possible to make it available for prescription at the same time as the drug master registration date. The adoption end date is the date on which the drug is removed from the list of drugs that can be prescribed and will no longer be prescribed. This is done due to reasons such as the drug becoming outdated or other effective drugs being released. In this case, instead of entering the end date of adoption, you can flag the drug as ineligible for prescription, or delete the drug record from the drug master. In addition to these items, you can also add columns such as the drug code, prescription amount, and precautions when prescribing. Figure 2 shows the drug master for the internal medicine department of Hospital A as an example, but drug masters may exist for each doctor as they are individually processed by the doctor, and in such cases, information about which doctor uses the drug master is also obtained. Conversely, drug masters may also exist for each medical institution. These drug masters are stored in the storage devices of medical systems such as electronic medical records used by each medical institution.

[0021] Returning to Figure 1, the drug analysis system 1 of this embodiment comprises a drug storage unit 10, a drug analysis unit 11, and an information provision unit 12.

[0022] The adopted drug storage unit 10 acquires drug information registered in the drug masters of multiple medical institutions A to C and stores it as adopted drug information. This adopted drug storage unit 10 primarily uses a storage device such as an HDD (hard disk drive) (not shown). The drug information acquired and stored includes, from the drug master shown in Figure 2, the drug name, pharmaceutical company, drug master registration date, prescription start date, and adoption end date. Information such as which medical institution and which department the drug master belongs to is also acquired.

[0023] The drug analysis unit 11 analyzes the drug information stored in the drug storage unit 10 to obtain analysis information. This drug analysis unit 11 is composed of a program for the drug analysis system 1 and a control device such as a CPU (not shown) working together. The analysis information is basically for users, and these users include at least one of the following: pharmaceutical companies and medical institutions. However, "at least one" refers only to detailed individual analysis information, and in many cases, the analysis information as a whole is provided to both pharmaceutical companies and medical institutions. Furthermore, even individual analysis information may be provided to both pharmaceutical companies and medical institutions. Individual analysis information will be explained later.

[0024] The information provision unit 12 provides analysis information to users, which are pharmaceutical companies and / or medical institutions. For example, the information provision unit 12 transmits analysis information in response to a request from a user's terminal device connected via the telecommunications line 3, and displays the analysis information on the user's terminal device screen. In this case, it is preferable to keep the name of the medical institution anonymous. Provision in paper format is also possible.

[0025] Next, referring to Figure 3, the types of analytical information analyzed by the adopted drug analysis unit 11 will be explained. Analytical information can be broadly divided into target drug information and comparison drug information. First, the target drug information on the left side of Figure 3 will be explained. Target drug information is analytical information about a specific drug that is the target. Target drug information is mainly analytical information for pharmaceutical companies, but it can also be used for medical institutions. Furthermore, by using target drug information for multiple drugs, it is possible to compare the analytical information of multiple drugs. Examples of target drug information include master adoption rate, adoption / deletion rate, adoption speed, prescription availability speed, registration usage period, in-hospital prescription adoption rate, outpatient prescription adoption rate, frequently used drug adoption rate, provisional adoption rate, etc.

[0026] Before explaining the details of the target drug information, let's refer to Figure 4 to explain the premise of the analysis. Here, as shown at the top of the table in Figure 4, we are analyzing information as of March 31, 2024, for a specific drug, "Drug A". We are also analyzing 10 medical institutions, from Hospital A to Hospital J. Looking at the "Drug Master Prescription Available" column in these medical institutions, a "1" in the cell indicates that the drug is registered in the drug master and is available for prescription (hereinafter, "registered in the drug master and available for prescription" may be expressed as "adopted"). Being available for prescription means that the drug is registered in the drug master shown in Figure 2, the prescription start date has passed, and the adoption end date has not passed. However, depending on the drug master's operation method, there may be cases where a drug is made available for prescription as soon as it is registered in the drug master without setting a prescription start date, or where a flag indicating unavailability is used instead of an adoption end date, or where the record for that drug is deleted from the drug master. In such cases, being available for prescription means that the drug is registered in the drug master and is not unavailable for prescription.

[0027] The following section provides a detailed explanation of the target drug information. The master adoption rate, as shown in the "Prescription Available in Drug Master" column of Figure 4, represents the percentage of drug A that is registered in the drug master and is available for prescription. In this example, out of 10 medical institutions from Hospital A to Hospital J, 8 institutions (excluding Hospitals F and G) have registered drug A in their drug master and made it available for prescription. Therefore, dividing the number of adoptions (8) by the number of medical institutions (10) yields a master adoption rate of 80%. By looking at this master adoption rate, pharmaceutical companies can find out how many of their drugs are registered in the drug masters of medical institutions and are available for prescription. Furthermore, while Figure 4 shows analytical information regarding drug A, it is also possible to obtain information on the trends of other companies by looking at information on drugs from other pharmaceutical companies (the same applies to the adoption / deletion rate, adoption speed, prescription speed, registration usage period, in-hospital prescription adoption rate, outpatient prescription adoption rate, frequently used drug adoption rate, and provisional adoption rate described below).

[0028] The adoption removal rate, as shown in Figure 5, represents the rate at which drug A, after being registered in the drug master and designated as prescribable, is removed from the list of available prescriptions and designated as unprescriptionable. Methods for making drug A unprescriptionable include, for example, leaving the drug registered in the drug master but adding an adoption end date to the drug's record (see the "Adoption End Date" column in Figure 2), or deleting the drug from the drug master so that it does not appear on the doctor's prescription screen. In Figure 5, 1 is entered in the cell where drug A is registered in the drug master and designated as prescribable. As of March 31, 2024, 8 out of 10 medical institutions have registered drug A in the drug master and designated it as prescribable, resulting in an adoption count of 8. One year later, on March 31, 2025, Hospital C has designated drug A as unprescriptionable. This means that 7 medical institutions have designated it as prescribable, resulting in an adoption count of 7. In this case, subtracting 7 divided by 8 from 1 gives 0.125. Rounding this to a percentage, the adoption removal rate is 13%. Similarly, as of March 31, 2026, Hospitals A and E have also made drug A unavailable for prescription. As a result, five medical institutions have made it available for prescription, bringing the total number of prescriptions to five. In this case, the number of prescriptions has decreased from eight as of March 31, 2024, to five. Therefore, subtracting 5 divided by eight from 1 gives 0.375. Similarly, rounding this to a percentage, the adoption removal rate is 38%. Note that in this embodiment, the adoption removal rate is compared to the number of prescriptions (8) as of March 31, 2024, but figures for any period, such as year-on-year or month-on-month, may also be used. Also, the base number is set to eight as of March 31, 2024, but it may be set to 10, the number of medical institutions. This adoption removal rate allows pharmaceutical companies to understand the trend of their drugs becoming unavailable for prescription. Furthermore, if there is a trend of prescriptions being denied for their own drugs, they can work with medical institutions to encourage them to adopt alternative drugs.

[0029] The adoption rate, as shown in the "Adoption Rate (Days)" column in Figure 6, represents the time it takes for drug A to be registered in each medical institution's drug master from the start of its sale. Here, drug A's sale start date is January 8, 2024. Hospital A registered drug A in its drug master on January 12, 2024, resulting in an adoption rate of 4 days from January 8, 2024 to January 12, 2024. Similarly, Hospital B registered drug A in its drug master on February 19, 2024, resulting in an adoption rate of 42 days. The average number of days including these cases and other hospitals is the "Adoption Rate (Average)" at the bottom of the "Adoption Rate (Days)" column. Here, the "Adoption Rate (Average)" is 40 days. Note that Figure 6 shows figures as of March 31, 2026, as indicated above the table.

[0030] The prescription availability rate, as shown in the "Prescription Availability Rate (Days)" column in Figure 6, represents the time it takes for drug A to become available for prescription at each medical institution after its launch. Here, drug A's launch date is January 8, 2024. In contrast, hospital A's prescription availability date for drug A is January 28, 2024, resulting in a prescription availability rate of 20 days, from January 8, 2024 to January 28, 2024. Similarly, hospital B's prescription availability date is March 1, 2024, resulting in a prescription availability rate of 53 days. The average number of days including these hospitals and others is the "Prescription Availability Rate (Average)" at the bottom of the "Prescription Availability Rate (Days)" column. Here, the "Prescription Availability Rate (Average)" is 52 days. Pharmaceutical companies naturally want their new drugs to be prescribed as soon as possible after their launch. Therefore, the adoption rate and prescription rate mentioned above can be used as indicators of the rate at which a company's drugs are distributed.

[0031] There are two types of registered usage periods: "Registered Usage Period (Days) Deleted" and "Registered Usage Period (Days) Entirely". First, let's explain the "Registered Usage Period (Days) Deleted" column in Figure 6. This represents the period during which the drug A in question was registered in the medical institution's drug master and was available for prescription. Here, we are focusing on hospitals A, C, and E, which have already deleted the drug from the drug master or made it unavailable for prescription. In hospital A, the prescription start date for drug A in the drug master was January 28, 2024, and the end date of adoption (registration deletion date) was September 30, 2025. From these figures, the "Registered Usage Period (Days) Deleted" from the prescription start date to the end date of adoption is 611 days. Similarly, for hospital C it is 286 days, and for hospital E it is 726 days. The average of these days is represented as 541 days in the "Deleted Registered Usage Period (Average)" at the bottom of the column.

[0032] Next, let's explain the "Registered Usage Period (Days) All" column in Figure 6. This also represents the period during which the drug A in question was registered in the medical institution's drug master and was available for prescription. The difference from the "Registered Usage Period (Days) Deleted" column mentioned above is that "Registered Usage Period (Days) All" includes hospitals that were available for prescription at the time of aggregation. For example, as of March 31, 2026, hospitals B, D, H, I, and J were available to prescribe drug A. Therefore, we calculate the number of days from the date when prescriptions could be started in the drug master of each of these hospitals to the aggregation date of March 31, 2026. For example, in hospital B, the date when prescriptions could be started was March 1, 2024, and there are 760 days until the aggregation date of March 31, 2026. The average of these is shown at the bottom of the column as "All Registered Usage Periods (Average)" and is 674 days. Furthermore, for both "Registered Usage Period (Days) Deleted" and "Registered Usage Period (Days) All," the start of the aggregation period can be changed to the prescription start date, resulting in the "Drug Master Registration Date" column in Figure 6. Pharmaceutical companies want their drugs to be prescribed for as long a period as possible. For this reason, "Registered Usage Period (Days) Deleted" and "Registered Usage Period (Days) All" can be used as indicators.

[0033] The in-hospital dispensing adoption rate, as shown in the "In-hospital dispensing" column of Figure 4, represents the percentage of drug A that is registered in the drug master and designated as an in-hospital dispensing drug. In-hospital dispensing drugs are drugs that a medical institution provides to patients itself and can be prescribed to both inpatients and outpatients of that medical institution. In this example, there are 10 medical institutions, and 6 of them have drug A as an in-hospital dispensing drug. Therefore, by dividing 6 by 10, the in-hospital dispensing adoption rate for drug A is 60%. Note that the denominator for calculating the in-hospital dispensing adoption rate is 10, the number of medical institutions that have registered drug A in the drug master and made it available for prescription, which is 8 (the "Prescriptionable in Drug Master" column in Figure 4), can also be used (the same applies to the outpatient dispensing adoption rate, frequently used drug adoption rate, and provisional adoption rate described later). Furthermore, regarding the method for specifying medications to be dispensed in-house, a new column may be added to the medication master shown in Figure 2, or a new table may be created to serve as the in-house prescription master (the same applies to the outpatient prescription adoption rate, frequently used medication adoption rate, and provisional adoption rate described later).

[0034] The outpatient prescription adoption rate, as shown in the "Outpatient Prescription" column of Figure 4, represents the percentage of drug A that is registered in the drug master and designated as an outpatient prescription drug. An outpatient prescription drug is a drug that is dispensed to a patient by an external pharmacy based on a prescription issued by a medical institution. In this case, there are 10 medical institutions, and 4 of them dispense drug A as an outpatient prescription drug. Therefore, by dividing 4 by 10, the outpatient prescription adoption rate for drug A is 40%.

[0035] The above-mentioned in-hospital dispensing rate and outpatient dispensing rate refer to the following: Pharmaceutical companies prefer in-hospital dispensing because it increases the number of dispensing opportunities. On the other hand, medical institutions often prefer outpatient dispensing because in-hospital dispensing increases the cost of drug management. By knowing the in-hospital dispensing rate and outpatient dispensing rate for the drugs they are interested in, pharmaceutical companies and medical institutions can use this information to inform their future actions.

[0036] The adoption rate of frequently used drugs, as shown in the "Frequently Used Drugs" column of Figure 4, represents the percentage of drug A that is registered in the drug master and designated as a frequently used drug. A frequently used drug is a drug that is frequently prescribed within the drug master. In other words, it is assumed that the drug is available for prescription. In this case, there are 10 medical institutions, and 5 of them designate drug A as a frequently used drug. Therefore, by dividing 5 by 10, the adoption rate of drug A as a frequently used drug is 50%. Pharmaceutical companies hope that their drugs will be designated as frequently used drugs, meaning they will be prescribed more often.

[0037] The provisional adoption rate, as shown in the "Provisional Adoption" column of Figure 4, represents the percentage of drug A that is registered in the drug master and designated as provisionally adopted. Provisional adoption is used by hospitals when adopting new drugs, for example, when considering safety. For example, provisional adoption could mean registering the drug in the drug master but not being able to prescribe it, or prescribing it only to a select group of patients who meet certain conditions. In this example, there are 10 medical institutions, and 1 of them has provisionally adopted drug A. Therefore, by dividing 1 by 10, the provisional adoption rate for drug A is 10%.

[0038] Next, we will explain the comparative drug information shown on the right side of Figure 3. Comparative drug information is analytical information that compares multiple drugs. While comparative drug information is primarily analytical information for medical institutions, it can also be used by pharmaceutical companies. Examples of comparative drug information include information on adopted drugs, information on drugs to be removed, information on drugs to be adopted, information on differences between manufacturers, information on drugs to be considered for adoption within a group, information on drugs adopted within a hospital, and information on frequently used drugs.

[0039] Before explaining this comparative drug information, let's refer to Figure 14 to explain the hospital master table. The hospital master table is a table that stores the region where hospitals A to J are located, the number of beds, the number of doctors, the number of medical departments, and the group name. The region is listed here at the prefectural level; for example, hospital A is located in Tokyo. This region could be a smaller unit such as Nerima Ward, or a larger unit such as Kanto. It is also possible to store both small and large units. The number of beds, the number of doctors, and the number of medical departments are approximate indicators of the size of the hospital. The number of beds and the number of doctors can be further subdivided into figures for each medical department. The group name is used to see which group the hospital belongs to. For example, hospitals A, D, and E belong to the same group, "Tosenkai".

[0040] Let's return to the explanation of comparative drug information. As shown in Figure 7, the comparative drug adoption information represents the adoption rate of each drug, indicating that it is registered and available for prescription in the drug master databases of multiple medical institutions. Here, it shows how many times each of the five drugs, from drug A to drug E, is registered and available for prescription in the drug master databases of 10 medical institutions, from Hospital A to Hospital J. For example, drug A is available for prescription in 8 hospitals, and the number of adoptions is 8. Dividing 8 by 10 gives the comparative drug adoption information for drug A as 80%. Similarly, drug B has an adoption of 7, and the comparative drug adoption information is 70%. By looking at this comparative drug adoption information for each drug, we can see which drugs from which pharmaceutical companies are widely adopted, and conversely, which drugs from which pharmaceutical companies are not adopted. This comparative drug adoption information is obtained by arranging the "Drug Master" column in Figure 4 by drug and pharmaceutical company. This comparative drug adoption information can also be aggregated by hospital region and size.

[0041] The drug information for deletion candidates, as shown in the row labeled "Only used at our hospital" in Figure 8, refers to drugs that are registered in the drug master of a specific medical institution and are available for prescription, but are not registered in or available for prescription in the drug masters of other medical institutions. Here, as an example, Hospital A, which is our own hospital, is considered the specific medical institution. Hospitals B and C, which are of a similar size to Hospital A, are considered other medical institutions. Here, hospitals with 201 to 300 beds are considered hospitals of similar size (see Figure 14). Comparing the drugs registered in the drug masters of these hospitals and available for prescription, drugs A and B are used by both our hospital and the other hospitals (symbol α). Drugs A and B are considered to be drugs widely used in medical institutions, so they will not be further examined here. Drugs C and E are used only at our hospital (symbol β). Drugs C and E, which are used only at our hospital, become the drug information for deletion candidates. This is because if our hospital uses more drugs than other hospitals, the management costs increase accordingly. Therefore, we will identify medications that are only used at our hospital and consider whether they can be deemed ineligible for prescription.

[0042] The candidate drug information, as shown in the row labeled "Only other hospitals use this drug" in Figure 8, refers to information about drugs that are not registered in or are not available for prescription in a specific medical institution's drug master, but are registered in and available for prescription in other medical institutions' drug masters. Here, as before, Hospital A is the specific medical institution, and Hospitals B and C of similar size are the other medical institutions. Comparing the drugs registered in and available for prescription in the drug masters of these hospitals, drugs A and B are used by both our hospital and the other hospitals (symbol α). Drugs A and B will not be considered again, as before. Drug D is not used by our hospital, but is used only by the other hospitals (symbol γ). Drug D, which is used only by the other hospitals, becomes the candidate drug information. This is because drug D, which is used only by the other hospitals, has a track record of being used to some extent in the market. Conversely, if there is a drug that is not used by any hospital, that drug may also become the candidate drug information. This is used when we want to use a drug that is not used by other hospitals. While this information on drugs to be removed and drugs to be adopted is compared among hospitals with similar numbers of beds, it is also possible to compare hospitals with similar numbers of doctors or medical departments, or hospitals in the same region.

[0043] As shown in Figure 9, manufacturer difference information represents the market share of each pharmaceutical company among the drugs registered in the drug master and available for prescription at each medical institution. Here, drug A is used in 8 hospitals. Similarly, drug B is used in 7, drug C in 6, drug D in 5, and drug E in 2, for a total of 28 adoptions. Dividing the number of adoptions for company A, which sells drug A, by 8 (total adoptions) gives a manufacturer market share of 29%. Similarly, company B, which sells drug B, has a manufacturer market share of 25%. This manufacturer difference information can also be used to analyze the market share of generic drugs or which pharmaceutical companies produce the most generic drugs. Here, drug D, sold by generic company X, accounts for 18%, and drug E, sold by generic company Y, accounts for 7%. Adding these together, 25% represents the manufacturer market share of generic drugs. This manufacturer difference information can also be aggregated by hospital region and size.

[0044] The group-wide adoption consideration information, as shown in the row labeled "Adopted by some hospitals" in Figure 10, refers to drugs registered and available for prescription in the drug masters of only some of the hospitals within the group to which a specific medical institution belongs, based on a comparison of the drug masters of the medical institutions within the group. Here, Hospital A, our own hospital, is designated as the specific medical institution. Hospitals D and E are also designated as hospitals belonging to the same group as Hospital A, "Tosenkai" (see Figure 14). Looking at Figure 10, drugs A and C are adopted by all hospitals in the group (symbol δ). On the other hand, drugs B, D, and E are adopted by only some hospitals (symbol ε). As a result, drugs A and C can be managed centrally within the group. Furthermore, it is possible to consider discontinuing the adoption of drugs B, D, and E.

[0045] As shown in Figure 11, in-hospital drug information refers to drugs that are registered as in-hospital prescription drugs in a specific medical institution's drug master but not in the drug masters of other medical institutions, based on a comparison of drug masters from multiple medical institutions. Here, we will look at Figure 11 with Hospital A, our own hospital, as the specific medical institution. Hospital A uses drugs A, B, and C as in-hospital prescription drugs. The in-hospital prescription adoption rates for drugs A through E among medical institutions from Hospital A to Hospital J are 60% for drug A, 30% for drug B, 30% for drug C, 20% for drug D, and 0% for drug E. In other words, drug A is also widely adopted as an in-hospital prescription drug in other hospitals, and it is considered that there is no problem in continuing to adopt drug A as an in-hospital prescription drug in Hospital A. On the other hand, the adoption rates for drugs B and below are not as high. From this, Hospital A can consider removing drugs B and C from its in-hospital prescription drug list (symbol ζ). This is because, for medical institutions, reducing the number of in-house prescribed medications makes drug management easier. On the other hand, for pharmaceutical companies, knowing the in-house prescription adoption rates of other companies allows them to compare their own drugs with those of other companies. The in-house prescription drug information shown in Figure 11 is a list of in-house prescription adoption rates for each drug, as shown in Figure 4. This in-house prescription drug information can also be used to compare hospitals of similar size or hospitals in the same region.

[0046] As shown in Figure 12, frequently used drug information refers to drugs that are registered as frequently used drugs in the drug master of a specific medical institution but not in the drug master of other medical institutions, based on a comparison of drug masters from multiple medical institutions. Here, let's look at Figure 12 with Hospital A as the specific medical institution. Hospital A uses drugs A and C as frequently used drugs. Here, the frequently used drug adoption rates for drugs A through E among medical institutions from Hospital A to Hospital J are 50% for drug A, 30% for drug B, 20% for drug C, 10% for drug D, and 0% for drug E. From this, we can see the trends for each drug, and it can be seen that it is reasonable for Hospital A to adopt drug A as a frequently used drug, but there is room for consideration regarding drug C (symbol η). On the other hand, pharmaceutical companies can also compare their drugs with those of other companies. Note that the frequently used drug information shown in Figure 12 is a list of frequently used drug adoption rates from Figure 4 arranged by drug. This information on frequently used medications can also be used to compare hospitals of similar size or those located in the same area.

[0047] Furthermore, as shown in Figure 13, frequently used drug information can also be counted for each physician by creating a frequently used drug master (not shown). In this case, since multiple numbers may be counted for a single hospital, the frequently used drug adoption rate at the bottom may exceed 100%.

[0048] As explained above, the drug analysis system 1 of this embodiment performs analysis based on drugs registered in the drug master, making it possible to perform analysis on virtually all drugs registered in the drug master. Furthermore, generally, obtaining data from prescription orders can lead to increased hardware load due to the need to process prescription orders that are frequently updated or accumulated. On the other hand, the drug analysis system 1 of this embodiment obtains data from a drug master that is updated relatively infrequently. Therefore, the hardware load can be reduced.

[0049] Furthermore, for pharmaceutical companies to have their drugs prescribed by physicians, it is essential that the physicians register their drugs in the drug master database of the medical institutions to which those physicians belong. Therefore, by observing trends and developments in the drug master database, they can use it as an indicator for their sales activities. In addition, medical institutions can view the status of drug master databases of other medical institutions, which can be used as a reference when adopting drugs themselves or when removing drugs that they have already adopted by making them unavailable for prescription.

[0050] The above-described drug analysis system 1 is an example of the present invention, and its configuration can be appropriately modified without departing from the spirit of the invention. [Explanation of Symbols]

[0051] 1. Drug analysis system, 2,3. Telecommunication lines, 10. Drug Acquisition Memory Department, 11. Drug Acquisition Analysis Department, 12. Information Provision Department

Claims

1. A drug storage unit that retrieves drug information registered in the drug masters of multiple medical institutions and stores it as adopted drug information, A drug analysis department analyzes the aforementioned drug adoption information to obtain analytical information for users, including at least one of the pharmaceutical companies and medical institutions. An information provision unit that provides the aforementioned analysis information to the user, A drug analysis system characterized by having the following features.

2. The aforementioned analysis information includes target drug information relating to the drug in question. The aforementioned drug information, The master adoption rate represents the percentage of the target drug that is registered in the drug master and is available for prescription, and The adoption / deletion rate represents the percentage of drugs that, after being registered in the drug master and deemed prescribable, are subsequently removed from the list of drugs that can be prescribed and are therefore deemed unprescriptionable. A drug analysis system according to claim 1, comprising:

3. The aforementioned analysis information includes target drug information relating to the drug in question. The aforementioned drug information, The adoption speed is the period from the start of sales of the drug to its registration in the drug master database. The prescription speed of the drug in question is the period from the start of sales of the drug until it becomes available for prescription. The period during which the drug in question was registered in the drug master and available for prescription is the registration usage period. The in-hospital prescription adoption rate represents the percentage of the target drug that is registered in the drug master and designated as an in-hospital prescription drug that can be dispensed within the hospital. The outpatient prescription adoption rate represents the percentage of the target drug that is registered in the drug master and designated as an outpatient prescription drug that can be prescribed outside the hospital. The frequently used drug adoption rate represents the percentage of the target drug that is registered in the drug master and designated as a frequently used drug. The provisional adoption rate represents the percentage of the target drug that is registered in the drug master and designated as provisionally adopted. The drug analysis system according to claim 1, comprising one or more of the following:

4. The aforementioned analysis information includes comparative drug information that compares multiple drugs, The aforementioned comparative drug information, Drug adoption comparison information, which represents the adoption rate of individual drugs registered and available for prescription in drug masters at multiple medical institutions. Information on drugs that are candidates for deletion, specifically drugs that are registered in the drug master data of a particular medical institution and are available for prescription, but are not registered in or available for prescription in the drug master data of other medical institutions. Information on potential drugs to be adopted, regarding drugs that are not registered in or are not available for prescription at a specific medical institution, but are registered in and available for prescription at another medical institution's drug master. Manufacturer-specific information representing the market share of each pharmaceutical company among drugs registered in the drug master database of multiple medical institutions and available for prescription. By comparing the drug master data of medical institutions within a group to which a specific medical institution belongs, information on the consideration of adopting drugs within the group regarding drugs that are registered in the drug master data of only some medical institutions within the group and are available for prescription is generated. A drug analysis system according to claim 1 or 2, comprising one or more of the following:

5. The aforementioned analysis information includes comparative drug information that compares multiple drugs, The aforementioned comparative drug information, Drug adoption comparison information, which represents the adoption rate of individual drugs registered and available for prescription in drug masters at multiple medical institutions. Information on drugs that are candidates for deletion, specifically drugs that are registered in the drug master data of a particular medical institution and are available for prescription, but are not registered in or available for prescription in the drug master data of other medical institutions. Information on potential drugs to be adopted, regarding drugs that are not registered in or are not available for prescription at a specific medical institution, but are registered in and available for prescription at another medical institution's drug master. Manufacturer-specific information representing the market share of each pharmaceutical company among drugs registered in the drug master database of multiple medical institutions and available for prescription. By comparing the drug master data of medical institutions within a group to which a specific medical institution belongs, information on the consideration of adopting drugs within the group regarding drugs that are registered in the drug master data of only some medical institutions within the group and are available for prescription is generated. A drug analysis system according to claim 3, comprising one or more of the following:

6. Information on in-house prescribed medications for drugs that are registered as in-house prescribed medications in the drug master data of a specific medical institution, but are not registered as in-house prescribed medications in the drug master data of other medical institutions. Information on frequently used drugs that are registered as frequently used drugs in the drug master data of a specific medical institution, but are not registered as frequently used drugs in the drug master data of other medical institutions. The drug analysis system according to claim 5, comprising one or more of the following:

Images